Quantcast

Latest Cancer organizations Stories

2014-09-07 20:20:13

Entertainment Industry, Corporate and Organizational Donors, Philanthropists, Health Charities, Government Entities, Volunteer Teams and the General Public Come Together to Fight Cancer LOS ANGELES, Sept. 7, 2014 /PRNewswire-USNewswire/ -- More than USD $109 million has been pledged so far in connection with the star-studded September 5 Stand Up To Cancer (SU2C) "roadblock" fundraising telecasts in the U.S. and Canada, it was announced today. The funds pledged toward the SU2C...

2014-09-05 23:03:59

Cross-platform campaign celebrates the collaborative research and innovations in cancer care, and highlights the further efforts needed on the path to finding a cure New York, NY (PRWEB) September 05, 2014 Mediaplanet today announces the distribution of the latest edition of “The Fight Against Cancer,” a cross-platform campaign which showcases innovations in cancer research and demands further attention around the topic. The industry has experienced a collaborative surge in research,...

2014-09-05 20:21:13

Komen Knoxville encourages fun-filled theme for breast cancer supporters KNOXVILLE, Tenn., Sept. 5, 2014 /PRNewswire/ -- Susan G. Komen Knoxville readies the finish line for the 2014 Race for the Cure on October 18(th) at World's Fair Park. To view the multimedia assets associated with this release, please click http://www.multivu.com/players/English/7313552-komen-knoxville-laces-up-for-2014-race-for-the-cure-do-you-tutu/ This year's "Do You Tutu?" theme will attract a variety of...

2014-09-04 23:05:39

Research takes another step closer to clinical trials. Chicago, IL (PRWEB) September 04, 2014 The American Brain Tumor Association (ABTA) Discovery Grant funding of high-risk, high-impact projects continues to be a catalyst for moving innovative treatment concepts closer to the clinic. Recently, Curtana Pharmaceuticals, a privately-held, preclinical stage pharmaceutical company announced that they will continue their OLIG2 inhibitor research—research initially funded by an ABTA...

2014-09-04 23:00:36

Family honors daughter and Pediatric Cancer Awareness Month with series of events to raise awareness Indianapolis, Indiana (PRWEB) September 05, 2014 Cancer is one of the leading killers of children in America, but funding for pediatric cancer research has lagged in recent years. More than 20 percent of pediatric cancer victims do not survive, and they would benefit from more research. September is designated as Pediatric Cancer Awareness Month, and in honor of this month and their...

2014-09-04 12:26:30

Dr. Drew Pinsky's personal battle with prostate cancer inspires him to join forces with PCF SANTA MONICA, Calif., Sept. 4, 2014 /PRNewswire-USNewswire/ -- The Prostate Cancer Foundation (PCF) announced that Drew Pinsky, MD has been elected to the Board of Directors. "Drew has valuable experience in internal and addiction medicine," said Jonathan W. Simons, MD, president and CEO of PCF. "As one of approximately 16 million prostate cancer survivors worldwide, Drew brings personal...

2014-09-04 08:30:46

Pennsylvania physicians say beating it begins with communications HARRISBURG, Pa., Sept. 4, 2014 /PRNewswire-USNewswire/ -- The simple fact of life for men is that as they age the risk of prostate cancer increases. And, it's one of those things that men cringe about. Statistics from the Centers for Disease Control and Prevention (CDC) show increasing risk as men age from their 50s into their 60s and then 70s. With the exception of skin cancer, the CDC says prostate cancer is the most common...

2014-09-04 08:30:25

BURLINGAME, Calif., Sept. 4, 2014 /PRNewswire/ -- Cleave Biosciences today announced that it has begun a Phase 1 clinical trial to evaluate its lead drug candidate, CB-5083, in patients with relapsed and refactory multiple myeloma. CB-5083 is a first-in-class, oral inhibitor of p97, a critical enzyme that controls various aspects of protein homeostasis. The open-label, Phase 1 dose escalation/dose expansion trial will evaluate the safety, pharmacokinetics, pharmacodynamics and...

2014-09-04 08:29:58

OneBlood Partnership helps iSpecimen Meet Need for Human Biospecimens LEXINGTON, Mass., Sept. 4, 2014 /PRNewswire/ -- iSpecimen®, a provider of on-demand human biospecimens to the life science community, announced today that it has secured $8 million in capital in its Series B Financing. New investor OneBlood(TM), Inc., through a wholly owned subsidiary, in conjunction with existing investors, will help grow iSpecimen's healthcare partner network and scale operations to meet the...

2014-09-03 23:05:54

Global research initiative to investigate long-term glioblastoma survivors. Chicago, IL (PRWEB) September 03, 2014 The American Brain Tumor Association (ABTA), in conjunction with the Brain Tumor Funder’s Collaborative (BTFC), is awarding a $2 million research grant to explore commonalities among long-term glioblastoma survivors around the world. Glioblastoma is a common and aggressive type of brain tumor most prevalent in adults ages 45-65, and affects more men than women. This highly...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.